<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7362761\results\search\disease\results.xml">
  <result pre="Department of Zoology, School of Biological Sciences, Dr. Harisingh Gour" exact="Central" post="UniversitySagarIndia[], 5Department of Chemistry, Rajshahi UniversityRajshahiBangladesh[], 6Department of Pharmacology,"/>
  <result pre="Calina calinadaniela@gmail.com Javad Sharifi-Rad javad.sharifirad@gmail.com This article was submitted to" exact="Infectious" post="Diseases â€&quot; Surveillance, Prevention and Treatment, a section of"/>
  <result pre="calinadaniela@gmail.com Javad Sharifi-Rad javad.sharifirad@gmail.com This article was submitted to Infectious" exact="Diseases" post="â€&quot; Surveillance, Prevention and Treatment, a section of the"/>
  <result pre="from their surface. An outbreak of a novel coronavirus 2019" exact="infection" post="has posed significant threat to the health and economies"/>
  <result pre="and economies in the whole world. This article reviewed the" exact="viral" post="replication, pathogenicity, prevention and treatment strategies. With a lack"/>
  <result pre="for this virus, alternative approaches to control the spread of" exact="disease" post="is in urgent need. This article also covers some"/>
  <result pre="a member of Î²-coronaviruses. It is genetically related to the" exact="Severe" post="Acute Respiratory Syndromeâ€&quot;Human coronavirus (SARS-CoV) and the Middle-East Respiratory"/>
  <result pre="member of Î²-coronaviruses. It is genetically related to the Severe" exact="Acute" post="Respiratory Syndromeâ€&quot;Human coronavirus (SARS-CoV) and the Middle-East Respiratory Syndromeâ€&quot;Human"/>
  <result pre="of Î²-coronaviruses. It is genetically related to the Severe Acute" exact="Respiratory" post="Syndromeâ€&quot;Human coronavirus (SARS-CoV) and the Middle-East Respiratory Syndromeâ€&quot;Human coronavirus"/>
  <result pre="the Severe Acute Respiratory Syndromeâ€&quot;Human coronavirus (SARS-CoV) and the Middle-East" exact="Respiratory" post="Syndromeâ€&quot;Human coronavirus MERS-CoV (3â€&quot;5). The pandemic SARS-CoV-2 outbreak has"/>
  <result pre="Syndromeâ€&quot;Human coronavirus MERS-CoV (3â€&quot;5). The pandemic SARS-CoV-2 outbreak has caused" exact="infection" post="in over 8,000,000 individuals and over 400,000 deaths in"/>
  <result pre="increasing at an alarming rate. The emergence of the SARS-COV-2" exact="disease" post="requires exploration and elucidation for a better understanding of"/>
  <result pre="its sources, production, transmission mechanism, prevention, management, and control (8)." exact="Infection" post="with this virus leads to respiratory damage, which can"/>
  <result pre="management, and control (8). Infection with this virus leads to" exact="respiratory" post="damage, which can progress to pneumonia or damage to"/>
  <result pre="this virus leads to respiratory damage, which can progress to" exact="pneumonia" post="or damage to the whole body. The structure of"/>
  <result pre="virus was identified in record time, and the mechanisms of" exact="infection" post="were largely deciphered. These are the first steps to"/>
  <result pre="These are the first steps to develop the most important" exact="infection" post="control measures, in addition to prevention and hygiene (9)."/>
  <result pre="included. Clinical trials have been identified using the name COVID-19" exact="disease" post="on an index of studies into novel coronavirus pneumonia"/>
  <result pre="COVID-19 disease on an index of studies into novel coronavirus" exact="pneumonia" post="in the Chinese Clinical Trial Registry (10) and ClinicalTrials.gov."/>
  <result pre="in the Chinese Clinical Trial Registry (10) and ClinicalTrials.gov. Coronavirus" exact="Disease" post="2019 (COVID-19): A Brief Overview SARS-CoV-2 is a Î²-coronavirus"/>
  <result pre="could be therapeutic targets. Surround the RNA molecule are the" exact="viral" post="structural proteins, the most important of which is the"/>
  <result pre="(transmembrane proteinase-serine 2), a modification that facilitates the entry of" exact="viral" post="particles into the cell (12â€&quot;14). The COVID-19 outbreak has"/>
  <result pre="SARS-CoV-2 is mostly transmitted via inhalation (19) as the lung" exact="epithelial" post="cells are the primary target of the virus. SARS-COV-2"/>
  <result pre="via inhalation (19) as the lung epithelial cells are the" exact="primary" post="target of the virus. SARS-COV-2 may be manifested as"/>
  <result pre="of the virus. SARS-COV-2 may be manifested as an asymptomatic" exact="infection" post="or mild to severe pneumonia (20). COVID-19 patients may"/>
  <result pre="be manifested as an asymptomatic infection or mild to severe" exact="pneumonia" post="(20). COVID-19 patients may experience abnormal respiratory findings, higher"/>
  <result pre="mild to severe pneumonia (20). COVID-19 patients may experience abnormal" exact="respiratory" post="findings, higher leukocyte numbers, and increased levels of plasma"/>
  <result pre="22), decreased lymphocytes, elevated fibrinogen, neutrophil, lactic dehydrogenase, fibrinogen, and" exact="acute" post="hypoxic respiratory failure (23). These findings suggest that immunopathology"/>
  <result pre="lymphocytes, elevated fibrinogen, neutrophil, lactic dehydrogenase, fibrinogen, and acute hypoxic" exact="respiratory" post="failure (23). These findings suggest that immunopathology may also"/>
  <result pre="may also have a crucial role in the development of" exact="disease" post="severity [(24, 25); Figure 2]. Figure 2 The systemic"/>
  <result pre="of disease severity [(24, 25); Figure 2]. Figure 2 The" exact="systemic" post="and respiratory disorders caused by SARS-COV-2 infection. The incubation"/>
  <result pre="severity [(24, 25); Figure 2]. Figure 2 The systemic and" exact="respiratory" post="disorders caused by SARS-COV-2 infection. The incubation period of"/>
  <result pre="disorders caused by SARS-COV-2 infection. The incubation period of SARS-COV-2" exact="infection" post="is ~5.2 days. There are general similarities in the"/>
  <result pre="some unique clinical features that include the targeting of the" exact="lower" post="airway as evident by upper respiratory tract symptoms like"/>
  <result pre="include the targeting of the lower airway as evident by" exact="upper" post="respiratory tract symptoms like rhinorrhea, sneezing, and sore throat."/>
  <result pre="the targeting of the lower airway as evident by upper" exact="respiratory" post="tract symptoms like rhinorrhea, sneezing, and sore throat. ACE2,"/>
  <result pre="RNA-Dependent RNA Polymerase Gene; IL-1, interleukin 1; IL-6, interleukin-6; TNF-Î±," exact="tumor" post="necrosis alpha; PO2, partial pressure of oxygen; SNS, sympathetic"/>
  <result pre="IL-1, interleukin 1; IL-6, interleukin-6; TNF-Î±, tumor necrosis alpha; PO2," exact="partial" post="pressure of oxygen; SNS, sympathetic nervous system; HR, heart"/>
  <result pre="PO2, partial pressure of oxygen; SNS, sympathetic nervous system; HR," exact="heart" post="rate; SIRS, systemic inflammatory response syndrome. There is evidence"/>
  <result pre="of oxygen; SNS, sympathetic nervous system; HR, heart rate; SIRS," exact="systemic" post="inflammatory response syndrome. There is evidence that the SARS-CoV-2"/>
  <result pre="fecal-oral route, not just by coughing and sneezing (26). Fecal" exact="viral" post="RNA could be detected in some patients (27). Diarrhea"/>
  <result pre="Fecal viral RNA could be detected in some patients (27)." exact="Diarrhea" post="is not the only gastrointestinal disorder described in COVID-19"/>
  <result pre="detected in some patients (27). Diarrhea is not the only" exact="gastrointestinal disorder" post="described in COVID-19 diseases. Nausea and vomiting, discomfort or"/>
  <result pre="only gastrointestinal disorder described in COVID-19 diseases. Nausea and vomiting," exact="discomfort" post="or abdominal pain, and mild or moderate damage of"/>
  <result pre="genes (25). Direct immunofluorescence assay (IFA) is used to detect" exact="viral" post="antigens present in the specimen, whereas the total lymphocyte"/>
  <result pre="to detect viral antigens present in the specimen, whereas the" exact="total" post="lymphocyte count (TLC) and chest CT examination can also"/>
  <result pre="in the specimen, whereas the total lymphocyte count (TLC) and" exact="chest" post="CT examination can also be used in SARS-CoV-2 infections"/>
  <result pre="and chest CT examination can also be used in SARS-CoV-2" exact="infections" post="(23). Some diagnostic features along with the treatment targets"/>
  <result pre="GCSF, granulocyte colony-stimulating factor; IP-10, interferon gamma-induced protein 10; TNF-Î±," exact="tumor" post="necrosis factor alpha; MIP1, Macrophage Inflammatory Protein 1; MCP-1,"/>
  <result pre="gamma-induced protein 10; TNF-Î±, tumor necrosis factor alpha; MIP1, Macrophage" exact="Inflammatory" post="Protein 1; MCP-1, monocyte chemotactic protein-1; ALT, alanine transaminase;"/>
  <result pre="protein 10; TNF-Î±, tumor necrosis factor alpha; MIP1, Macrophage Inflammatory" exact="Protein" post="1; MCP-1, monocyte chemotactic protein-1; ALT, alanine transaminase; AST,"/>
  <result pre="tumor necrosis factor alpha; MIP1, Macrophage Inflammatory Protein 1; MCP-1," exact="monocyte" post="chemotactic protein-1; ALT, alanine transaminase; AST, aspartate transaminase; CRP,"/>
  <result pre="essential for the survival of the virus; (ii) Inhibition of" exact="viral" post="structural proteins, preventing interaction with human cells or virion"/>
  <result pre="with the cell membrane. Inhibits nucleic acid replication, glycosylation of" exact="viral" post="proteins, assembly of the virus, and release of the"/>
  <result pre="Inhibits TMPRSS2 protease Inhibition of cell entry Prevents SARS-CoV-2 coronavirus" exact="infection" post="An in vitro study in a mouse model demonstrated"/>
  <result pre="camostat in protecting mice from death from a lethal SARS-CoV" exact="infection" post="with a 60% survival rate (34). It is considered"/>
  <result pre="FDA (US) has authorized the use of remdesivir in severe" exact="infection" post="with the new coronavirus SARS-CoV-2, through the Special Emergency"/>
  <result pre="for HIV Lopinavir is a protease inhibitor used to treat" exact="HIV infection" post="in combination with ritonavir to increase its availability. Lopinavir"/>
  <result pre="HIV Lopinavir is a protease inhibitor used to treat HIV" exact="infection" post="in combination with ritonavir to increase its availability. Lopinavir"/>
  <result pre="virus. In the case of early administration, in the initial" exact="viral" post="phase, in the first 10 days after the onset"/>
  <result pre="days (37). This drug remains as another alternative, in the" exact="absence of" post="more effective drugs. An additional plus is related to"/>
  <result pre="(fusion inhibitor) and the immunomodulatory effect. In patients with uncomplicated" exact="pneumonia" post="in COVID-19, the combination of umifenovir (200 mg every"/>
  <result pre="times daily for duration of 7â€&quot;10 days or longer (39)." exact="Reduced" post="side effects Favipiravir Antiviral for flu and Ebola RNA"/>
  <result pre="patients, as well as a decrease in oxygen requirements and" exact="partial" post="correction of lymphopenia. The results obtained with tocilizumab combined"/>
  <result pre="3 administrations (40). Risks associated with the reactivation of tuberculosis," exact="hepatic cytolysis," post="hypercholesterolemia. Inhibitors of Cell Entry SARS-CoV-2 can only bind"/>
  <result pre="only bind to ACE2 receptors (activated mainly in people with" exact="chronic" post="diseases, while in healthy people ACE1 receptors are activated"/>
  <result pre="a possible therapeutic target due to its role as a" exact="viral" post="ligand. ACE2 is commonly found in the cells of"/>
  <result pre="an accessible target for coronavirus, which is transmitted through the" exact="respiratory" post="tract. In this regard, several molecules that could inhibit"/>
  <result pre="mesenchymal stem cells (41). Another way to act on the" exact="viral" post="receptor is with the help of recombinant human ACE2"/>
  <result pre="help of recombinant human ACE2 (rhACE2), a molecule studied in" exact="acute" post="respiratory distress syndrome (ARDS), due to the high level"/>
  <result pre="of recombinant human ACE2 (rhACE2), a molecule studied in acute" exact="respiratory" post="distress syndrome (ARDS), due to the high level of"/>
  <result pre="human ACE2 (rhACE2), a molecule studied in acute respiratory distress" exact="syndrome" post="(ARDS), due to the high level of ACE2 in"/>
  <result pre="which could be beneficial both by lowering viremia (due to" exact="limited" post="binding to the ECA2 receptor) and by protecting the"/>
  <result pre="by abrogating the infection, resulting in the inhibition of SARS-CoV-2" exact="infection" post="and spread (44). Emergence of the HCoV strains such"/>
  <result pre="such as OC43 (HCoV-OC43) caused a 15â€&quot;30% increase of mild" exact="upper" post="respiratory tract infections. Research findings showed that chloroquine inhibits"/>
  <result pre="as OC43 (HCoV-OC43) caused a 15â€&quot;30% increase of mild upper" exact="respiratory" post="tract infections. Research findings showed that chloroquine inhibits HCoV-OC43"/>
  <result pre="and it may be tested as a future drug against" exact="viral infection" post="and spread. The molecular mechanism of the action of"/>
  <result pre="it may be tested as a future drug against viral" exact="infection" post="and spread. The molecular mechanism of the action of"/>
  <result pre="Besides, they can also inhibit nucleic acid replication, glycosylation of" exact="viral" post="proteins, virus assembly, transport of new virus particles, and"/>
  <result pre="TMPRSS2 in cell culture studies and, implicitly, the inhibition of" exact="viral infection." post="Another inhibitor, nafamostat, used as an anticoagulant and anti-pancreatitis"/>
  <result pre="and anti-pancreatitis agent and is approved for the treatment of" exact="cystic fibrosis." post="Nafamostat has mucolytic action and can prevent the deterioration"/>
  <result pre="Drug Administration (FDA) has authorized the use of remdesivir in" exact="infections" post="with SARS-CoV-2, through the Special Emergency Use Authorization (EUA)."/>
  <result pre="patients with a suspected or confirmed severe form of the" exact="infection" post="(those who have blood oxygen saturation SpO2 â‰¤ 94%,"/>
  <result pre="even outside of clinical trials. However, EUA is not a" exact="complete" post="approval, as further studies are needed to confirm the"/>
  <result pre="The ACTT study, organized by the US National Institute of" exact="Allergic" post="and Infectious Diseases (NIAID) was a phase III, randomized,"/>
  <result pre="study, organized by the US National Institute of Allergic and" exact="Infectious" post="Diseases (NIAID) was a phase III, randomized, placebo-controlled trial"/>
  <result pre="organized by the US National Institute of Allergic and Infectious" exact="Diseases" post="(NIAID) was a phase III, randomized, placebo-controlled trial with"/>
  <result pre="groups. Half of the patients showed an improvement in the" exact="disease" post="in the first 10 days, in the case of"/>
  <result pre="a team of experts from Wuhan (the city where the" exact="infection" post="began) developed a best practice guide, following the management"/>
  <result pre="inhibits the enzyme reverse transcriptase), or with umifenovir (inhibitor of" exact="viral" post="fusion of human cell membranes, which inhibits the interaction"/>
  <result pre="tested in combination with other antivirals in patients with uncomplicated" exact="pneumonia" post="with COVID-19 (57). The combination of umifenovir with lopinavir/ritonavir"/>
  <result pre="or infections. In SARS-Cov-2 infection, favipiravir was more effective in" exact="viral" post="eradication and regression of lung imaging than both lopinavir/ritonavir"/>
  <result pre="for as long as necessary for treatment of a concomitant" exact="infection" post="with an influenza virus (60). Tocilizumab Tocilizumab is a"/>
  <result pre="tocilizumab (trade name Actemra) is therapeutically indicated for patients with" exact="rheumatoid arthritis," post="but Chinese authorities have stated that it can be"/>
  <result pre="stated that it can be prescribed for patients with coronavirus" exact="infection" post="who have severe lung damage and high levels of"/>
  <result pre="levels of interleukin 6 protein (IL-6), which indicates inflammation and" exact="immune disorders" post="(61). This immunomodulator may be used in a subgroup"/>
  <result pre="the 1890s. It was the only way to treat many" exact="infectious diseases" post="before the advent of antimicrobial therapy in the 1940s."/>
  <result pre="1940s. The convalescent plasma was also used during the 2013" exact="African" post="Ebola epidemic (62). Experience from previous coronavirus situations, such"/>
  <result pre="antiviral and immunomodulatory (63). Antibodies could work in several ways:" exact="Viral" post="neutralization: the antibody attaches to the virus and kills"/>
  <result pre="infected indices for the purpose of preventing or treating the" exact="disease" post="due to the pathogen. Currently the only antibody available"/>
  <result pre="with severe forms of COVID-19 hospitalized in ATI, with rapid" exact="disease" post="progression of&amp;gt; 50% in 24â€&quot;48 h (with lung damage,"/>
  <result pre="A team of experts from Wuhan (the city where the" exact="infection" post="occurred) developed a good practice guide, following the management"/>
  <result pre="inhibit the enzyme reverse transcriptase), or with umifenovir (inhibitor of" exact="viral" post="fusion by human cell membranes). SOLIDARITY trial is a"/>
  <result pre="is eliminated from the body (viral clearance from blood and" exact="respiratory" post="samples) and biological markers of its impact on the"/>
  <result pre="and it will include the same therapeutic molecules and a" exact="total" post="of 3,200 patients from Belgium, Germany, Luxembourg, the Netherlands,"/>
  <result pre="the clinical status in severe cases of SARS-COV-2, with advanced" exact="pulmonary" post="inflammation. This use is based on the approval of"/>
  <result pre="the approval of tocilizumab as a treatment in cytokine release" exact="syndrome" post="(CRS), an inflammatory manifestation throughout the body, which may"/>
  <result pre="with cytokine release (including IL-6), which stimulates fever, inflammation, and" exact="pulmonary" post="fibrosis. Studies of SARS-COV-2 cases have shown that elevated"/>
  <result pre="are statistically significantly correlated with the severe evolution of the" exact="infection" post="(71). To test the impact of camostat mesilate on"/>
  <result pre="(71). To test the impact of camostat mesilate on COVID-19" exact="Infection" post="(CamoCO-19), an Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial is"/>
  <result pre="fact that COVID-19 involves the activation of the coagulation cascade," exact="pulmonary embolism," post="and bacterial superinfections (73). Chloroquine phosphate displayed apparent efficacy"/>
  <result pre="involves the activation of the coagulation cascade, pulmonary embolism, and" exact="bacterial" post="superinfections (73). Chloroquine phosphate displayed apparent efficacy and acceptable"/>
  <result pre="in the Guidelines for the Prevention, Diagnosis, and Treatment of" exact="Pneumonia" post="Caused by SARS-CoV-2 issued by the National Health Commission"/>
  <result pre="SARS-COV-2 (74). Although chloroquine has long been used to treat" exact="malaria" post="and amebiasis, Plasmodium falciparum has developed widespread resistance to"/>
  <result pre="(75). Furthermore, an overdose of chloroquine was known to cause" exact="acute" post="poisoning and death (76) which limits its utilization in"/>
  <result pre="(77). Recently, hydroxychloroquine was found to efficiently inhibit the SARS-CoV-2" exact="infection" post="in vitro through an anti-inflammatory mechanism (48). In a"/>
  <result pre="mechanism (48). In a most recent report, hydroxychloroquine's role on" exact="respiratory" post="viral loads was evaluated using SARS-COV-2 patients from France"/>
  <result pre="(48). In a most recent report, hydroxychloroquine's role on respiratory" exact="viral" post="loads was evaluated using SARS-COV-2 patients from France (78)."/>
  <result pre="Hydroxychloroquine (600 mg daily) was administered to patients and their" exact="viral" post="load in nasopharyngeal swabs was tested daily. After 6"/>
  <result pre="of treatment, 20 cases showed a significant reduction of the" exact="viral" post="load. Interestingly, the addition of azithromycin to hydroxychloroquine significantly"/>
  <result pre="clinical survey demonstrated that hydroxychloroquine treatment is significantly associated with" exact="viral" post="load reduction in SARS-CoV-2 infected patients, with better results"/>
  <result pre="This might be a milestone preventive option in limiting the" exact="infection" post="and spread of SARS-CoV-2. In the case of umifenovir"/>
  <result pre="according to ongoing Chinese studies, it could lead to a" exact="lower" post="mortality rate. A randomized study compared umifenovir with another"/>
  <result pre="55.9% in the umifenovir group) (80). Other therapeutic options, with" exact="lower" post="chances of successâ€&quot;according to the WHOâ€&quot;are monoclonal or polyclonal"/>
  <result pre="serum collected from patients with SARS-COV-2, which contains antibodies against" exact="infection" post="(25). However, a study involving plasma harvested from patients"/>
  <result pre="cured of SARS-COV-2 and its administration in severe cases of" exact="pulmonary" post="disease has been initiatedâ€&quot;in which a few cases of"/>
  <result pre="of SARS-COV-2 and its administration in severe cases of pulmonary" exact="disease" post="has been initiatedâ€&quot;in which a few cases of clinical"/>
  <result pre="by WHO, recent studies suggest other possible treatments for SARS-CoV-2." exact="Mesenchymal" post="stem cells are the subject of several phase I"/>
  <result pre="of stem cells can inhibit the inflammatory component of SARS-COV-2" exact="lung disease" post="(which can lead to fatal disease progression) (84). Elements"/>
  <result pre="stem cells can inhibit the inflammatory component of SARS-COV-2 lung" exact="disease" post="(which can lead to fatal disease progression) (84). Elements"/>
  <result pre="component of SARS-COV-2 lung disease (which can lead to fatal" exact="disease" post="progression) (84). Elements of traditional Chinese medicine (TCM), such"/>
  <result pre="dead or weakened microorganisms of the virus that causes the" exact="disease" post="(or fragments, products, derivatives) stimulates the production of antibodies"/>
  <result pre="microorganism that causes the disease, then it itself prevents the" exact="disease" post="from reacting quickly and efficiently (87). The human immune"/>
  <result pre="fight the disease, this immunity results, providing protection against the" exact="disease" post="for many months, years, or even life. If a"/>
  <result pre="rapidly produce the same type of antibody that prevents the" exact="disease" post="from developing or decreases its severity and allows it"/>
  <result pre="different foreign organisms (89). Vaccination involves the introduction of a" exact="limited" post="amount of disease-specific antigens into the human body, which"/>
  <result pre="produce the required amount of antibodies but without causing the" exact="disease" post="(90). Vaccine development is a complex and time-consuming process"/>
  <result pre="2021. It will be conducted in the UK, on healthy" exact="adult" post="volunteers aged 18â€&quot;55. The vaccine will be administered intramuscularly."/>
  <result pre="based on a technological platform developed by Cansino, related to" exact="viral" post="adenoviruses. It is the same platform where a vaccine"/>
  <result pre="novel vaccine, developed by genetic engineering with the replication of" exact="type 5" post="adenovirus as a vector of immunity against the protein"/>
  <result pre="are used; (iii) the vaccine formula developed by KBP remains" exact="stable" post="at room temperature, as opposed to conventional vaccines, which"/>
  <result pre="that there are significant efforts to diagnose, treat, and prevent" exact="infections" post="with the new coronavirus. Alternative Medicationâ€&quot;Natural Compounds To Control"/>
  <result pre="natural products with immunostimulatory and antiviral action are recommended in" exact="respiratory" post="viruses and viral infections with various locations (100, 101)."/>
  <result pre="immunostimulatory and antiviral action are recommended in respiratory viruses and" exact="viral" post="infections with various locations (100, 101). They support immunity"/>
  <result pre="and antiviral action are recommended in respiratory viruses and viral" exact="infections" post="with various locations (100, 101). They support immunity and"/>
  <result pre="(102). These could serve as a cure and could prevent" exact="infection" post="and viral replication. Some TCM and other herbal preparations"/>
  <result pre="could serve as a cure and could prevent infection and" exact="viral" post="replication. Some TCM and other herbal preparations could resolve"/>
  <result pre="&amp;amp; Koidz.), may enhance immunity and be beneficial for CoV" exact="infection" post="treatment (106). However, further evidence is needed. Several traditional"/>
  <result pre="the replication of SARS-CoV-2 through inhibition of one or more" exact="viral" post="proteins including SARS-CoV-23CL protease. This protease is an important"/>
  <result pre="polypeptides into functional proteins, and plays a key role in" exact="viral" post="replication (114, 115). Thus, SARS-CoV-23CL protease can be a"/>
  <result pre="118) which adds to liver-protection during hepatic failure due to" exact="viral" post="proliferation. On the basis of these observations, other specific"/>
  <result pre="Japanese knotweed, exhibited antiviral activity against SARS-CoV. It inhibited the" exact="viral" post="entry into host cells by binding with the spike"/>
  <result pre="(124). Likewise, luteolin and quercetin could also interfere with the" exact="viral" post="entry to its host cells (125). Furthermore, tetra-O-galloyl-Î²-d-glucose (TGG)"/>
  <result pre="combat SARS-CoVs, but also play an important role in preventing" exact="viral" post="attacks. However, there is a lack of adequate research"/>
  <result pre="as new evidence emerges. Second, only data based on the" exact="adult" post="population and not the pediatric population were included in"/>
  <result pre="Drug development, together with vaccine development and epidemiological research into" exact="viral infection," post="is an essential element in understanding and controlling SARS-COV-2."/>
  <result pre="SARS-CoV-2 pandemic is related to a social together with its" exact="viral" post="catastrophe. The control of the outbreaks of SARS-CoV-2 is"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="could be construed as a potential conflict of interest. 1Coronavirus" exact="disease" post="2019 (COVID-19) treatment guideline. References References 1.BogochIiWattsAThomas-BachliAHuberCKraemerMUGKhanK. Pneumonia of"/>
  <result pre="interest. 1Coronavirus disease 2019 (COVID-19) treatment guideline. References References 1.BogochIiWattsAThomas-BachliAHuberCKraemerMUGKhanK." exact="Pneumonia" post="of unknown aetiology in Wuhan, China: potential for international"/>
  <result pre="Int J Infect Dis. (2020) 91:264â€&quot;66. 10.1016/j.ijid.2020.01.00931953166 3.ChanJFLauSKToKKChengVCWooPCYuenKY. Middle East" exact="respiratory" post="syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin"/>
  <result pre="J Infect Dis. (2020) 91:264â€&quot;66. 10.1016/j.ijid.2020.01.00931953166 3.ChanJFLauSKToKKChengVCWooPCYuenKY. Middle East respiratory" exact="syndrome" post="coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol"/>
  <result pre="Mol Med Rep. (2020) 22:20â€&quot;32. 10.3892/mmr.2020.1107932319647 7.collab: World Health OrganizationCoronavirus" exact="Disease" post="2019 (COVID-19). Situation Report - 66. March 27, 2020."/>
  <result pre="reevaluate the correlation between long-term effects of anthropogenic pollutants on" exact="viral" post="epidemic/pandemic events and prevalence. Food Chem Toxicol. (2020) 136:111418."/>
  <result pre="12.FarsalinosKNiauraRLe HouezecJBarbouniATsatsakisAKouretasDet al.. Nicotine and SARS-CoV-2: COVID-19 may be a" exact="disease" post="of the nicotinic cholinergic system. Toxicol Rep. (2020) 7:658â€&quot;63."/>
  <result pre="13.GuoYRCaoQDHongZSTanYYChenSDJinHJet al.. The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak - an update on the status."/>
  <result pre="COVID-19 outbreak. Curr Biol. (2020) 30:1346â€&quot;51.e2. 10.2139/ssrn.354258632197085 17.LuHStrattonCWTangYW. Outbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: the mystery and"/>
  <result pre="epidemic predictions. medRxiv. (2020). 10.1101/2020.01.23.20018549 20.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. (2020) 382:1708â€&quot;20."/>
  <result pre="al.. Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="clinical diagnosis and treatment of a case infected with coronavirus" exact="disease" post="2019. J Med Virol. (2020) 92:461â€&quot;3. 10.1002/jmv.2571132073161 24.DoceaAOGofitÄƒECalinaDZaharieSValceaDIMitru?PAutoimmune disorders"/>
  <result pre="double antiviral therapy with Peginterferon and Ribavirin in patients with" exact="hepatitis C" post="virus infection. Farmacia J. (2016) 64:605â€&quot;11. 25.CormanVMLandtOKaiserMMolenkampRMeijerAChuDKWet al.Detection of"/>
  <result pre="therapy with Peginterferon and Ribavirin in patients with hepatitis C" exact="virus infection." post="Farmacia J. (2016) 64:605â€&quot;11. 25.CormanVMLandtOKaiserMMolenkampRMeijerAChuDKWet al.Detection of 2019 novel"/>
  <result pre="Euro Surveill. (2020) 25:200004510.2807/1560-7917.ES.2020.25.3.2000045 26.LiuJLiaoXQianSYuanJWangFLiuYet al.. Community transmission of severe" exact="acute" post="respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg Infect"/>
  <result pre="Surveill. (2020) 25:200004510.2807/1560-7917.ES.2020.25.3.2000045 26.LiuJLiaoXQianSYuanJWangFLiuYet al.. Community transmission of severe acute" exact="respiratory" post="syndrome coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis."/>
  <result pre="(2020) 25:200004510.2807/1560-7917.ES.2020.25.3.2000045 26.LiuJLiaoXQianSYuanJWangFLiuYet al.. Community transmission of severe acute respiratory" exact="syndrome" post="coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. (2020)"/>
  <result pre="10.3390/pathogens903018632143502 29.Rodriguez-PalaciosACominelliFBassonAPizarroTIlicS. Textile masks and surface covers-a'universal droplet reduction model'against" exact="respiratory" post="pandemics. Front Med. (2020) 7:260. 10.1101/2020.04.07.2004561732574342 30.WuCLiuYYangYZhangPZhongWWangYet al.. Analysis"/>
  <result pre="Pharm Sin B. (2020) 10:766â€&quot;88. 10.1016/j.apsb.2020.02.00832292689 31.SkalnyAVRinkLAjsuvakovaOPAschnerMGritsenkoVAAlekseenkoSIet al.. Zinc and" exact="respiratory" post="tract infections: perspectives for COVID-19. Int J Mol Med."/>
  <result pre="of the index patient who caused tertiary transmission of coronavirus" exact="disease" post="2019 in Korea: the application of lopinavir/ritonavir for the"/>
  <result pre="Korea: the application of lopinavir/ritonavir for the treatment of COVID-19" exact="pneumonia" post="monitored by quantitative RT-PCR. J Korean Med Sci. (2020)"/>
  <result pre="is not associated with improved outcomes in patients with coronavirus" exact="disease" post="2019: a retrospective study. Clin Microbiol Infect. (2020) 26:917â€&quot;21."/>
  <result pre="Placebo Parallel-Controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus" exact="Pneumonia" post="vaccine (Vero cells). ChiCTR2000031809 (2020). Available online at: http://www.chictr.org.cn/"/>
  <result pre="cells). ChiCTR2000031809 (2020). Available online at: http://www.chictr.org.cn/ 42.collab: Apeiron BiologicsAPEIRON's" exact="Respiratory" post="Drug Product to Start Pilot Clinical Trial to Treat"/>
  <result pre="Drug Product to Start Pilot Clinical Trial to Treat Coronavirus" exact="Disease" post="COVID-19 in China. (2020). Available online at: https://www.apeiron-biologics.com 43.YaoXYeFZhangMCuiCHuangBNiuPet"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2020)"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2020) ciaa237."/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2020) ciaa237. 10.1093/cid/ciaa237."/>
  <result pre="44.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.. Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. (2005) 2:69. 10.1186/1743-422X-2-6916115318 45.GordonCJTchesnokovEPFengJYPorterDPGotteM. The"/>
  <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. J Biol Chem. (2020) 295:4773â€&quot;9. 10.1074/jbc.AC120.01305632094225 46.KeyaertsELiSVijgenLRysmanEVerbeeckJVan"/>
  <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. J Biol Chem. (2020) 295:4773â€&quot;9. 10.1074/jbc.AC120.01305632094225 46.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet"/>
  <result pre="RanstMet al.. Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn mice. Antimicrob Agents Chemother. (2009) 53:3416â€&quot;21. 10.1128/AAC.01509-0819506054"/>
  <result pre="53:3416â€&quot;21. 10.1128/AAC.01509-0819506054 47.RogoveanuOCCalinaDCucuMGBuradaFDoceaAOSosoiSet al.. Association of cytokine gene polymorphisms with" exact="osteoarthritis" post="susceptibility. Exp Ther Med. (2018) 16:2659â€&quot;64. 10.3892/etm.2018.647730186498 48.LiuJCaoRXuMWangXZhangHHuHet al.."/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro. Cell Discov. (2020) 6:16. 10.1038/s41421-020-0156-032194981 49.YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIet al.."/>
  <result pre="Identification of nafamostat as a potent inhibitor of middle east" exact="respiratory" post="syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based"/>
  <result pre="of nafamostat as a potent inhibitor of middle east respiratory" exact="syndrome" post="coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell"/>
  <result pre="assay. Antimicrob Agents Chemother. (2016) 60:6532â€&quot;9. 10.1128/AAC.01043-1627550352 50.BurkiTOutbreak of coronavirus" exact="disease" post="2019. Lancet Infect Dis. (2020) 20:292â€&quot;3. 10.1016/S1473-3099(20)30076-132078809 51.ZhouYHouYShenJHuangYMartinWChengF. Network-based"/>
  <result pre="10.1038/s41421-020-0153-332194980 52.collab: NIHNIH Clinical Trial Shows Remdesivir Accelerates Recovery from" exact="Advanced" post="COVID-19. National Institute of Allergy and Infectious Diseases (NIH)"/>
  <result pre="Accelerates Recovery from Advanced COVID-19. National Institute of Allergy and" exact="Infectious" post="Diseases (NIH) (2020). Available online at: https://www.niaid.nih.gov/news-events/ (accessed April"/>
  <result pre="Recovery from Advanced COVID-19. National Institute of Allergy and Infectious" exact="Diseases" post="(NIH) (2020). Available online at: https://www.niaid.nih.gov/news-events/ (accessed April 24,"/>
  <result pre="Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With" exact="Severe" post="COVID-19. (2020). Available online at: https://www.gilead.com/news-and-press/ (accessed April 20,"/>
  <result pre="57.JiemingQUClinical Study of Arbidol Hydrochloride Tablets in the Treatment of" exact="Pneumonia" post="Caused by Novel Coronavirus. NCT04260594 (2020). Available online at:"/>
  <result pre="(2020). Available online at: https://clinicaltrials.gov/ (accessed April 1, 2020). 58.KadamRUWilsonIA." exact="Structural" post="basis of influenza virus fusion inhibition by the antiviral"/>
  <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China. JAMA. (2020) 323:1061â€&quot;9. 10.1001/jama.2020.158532031570 61.XuXHanMLiTSunWWangDFuBet al.."/>
  <result pre="March 24, 2020). 67.collab: NHSWho Can Donate Convalescent Plasma? NHS" exact="Blood" post="and Transplant. (2020). Available online at: https://www.nhsbt.nhs.uk/ (accessed April"/>
  <result pre="April 16, 2020). 68.ArabiYMAlothmanABalkhyHHAl-DawoodAAljohaniSAl HarbiSet al.. Treatment of Middle East" exact="Respiratory" post="Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE"/>
  <result pre="16, 2020). 68.ArabiYMAlothmanABalkhyHHAl-DawoodAAljohaniSAl HarbiSet al.. Treatment of Middle East Respiratory" exact="Syndrome" post="with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial):"/>
  <result pre="Evaluate the Safety and Efficacy of Tocilizumab in Patients With" exact="Severe" post="COVID-19 Pneumonia (COVACTA). NCT04320615 (2020). Available online at: https://clinicaltrials.gov/"/>
  <result pre="Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19" exact="Pneumonia" post="(COVACTA). NCT04320615 (2020). Available online at: https://clinicaltrials.gov/ (accessed April"/>
  <result pre="72.collab: University of AarhusThe Impact of Camostat Mesilate on COVID-19" exact="Infection" post="(CamoCO-19). NCT04321096 (2020). Available online at: https://clinicaltrials.gov/ (accessed April"/>
  <result pre="print].32205204 79.UngureanuAZlatianOMitroiGDrocaÅŸATÃ®rcÄƒTCÄƒlinaDet al.. Staphylococcus aureus colonisation in patients from a" exact="primary" post="regional hospital. Mol Med Rep. (2017) 16:8771â€&quot;80. 10.3892/mmr.2017.774629039613 80.SandersJMMonogueMLJodlowskiTZCutrellJB."/>
  <result pre="Med Rep. (2017) 16:8771â€&quot;80. 10.3892/mmr.2017.774629039613 80.SandersJMMonogueMLJodlowskiTZCutrellJB. Pharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19): a review. JAMA. (2020) 323:1824â€&quot;36. 10.1001/jama.2020.601932282022 81.ChenLXiongJBaoLShiY."/>
  <result pre="and anti-inflammatory treatments. Lancet Infect Dis. (2020) 20:400â€&quot;2. 10.1016/S1473-3099(20)30132-832113509 84.ShettyAK." exact="Mesenchymal" post="stem cell infusion shows promise for combating coronavirus (COVID-19)-"/>
  <result pre="Int J Biol Sci. (2020) 16:1708â€&quot;17. 10.7150/ijbs.4553832226288 86.BodaDDoceaAOCalinaDIlieMACaruntuCZuracSet al.. Human" exact="papilloma" post="virus: apprehending the link with carcinogenesis and unveiling new"/>
  <result pre="LeTHendersonKKaloudisADanielsenTHammerslandNCet al.. Estimating the cost of vaccine development against epidemic" exact="infectious" post="diseases: a cost minimisation study. Lancet Glob Health. (2018)"/>
  <result pre="from Ebola. N Engl J Med. (2015) 372:1381â€&quot;4. 10.1056/NEJMp150291825853741 89.RatajczakWNiedzwiedzka-RystwejPTokarz-DeptuÅ‚aBDeptuÅ‚aW." exact="Immunological" post="memory cells. Central Eur J Immunol. (2018) 43:194â€&quot;203. 10.5114/ceji.2018.7739030135633"/>
  <result pre="Engl J Med. (2015) 372:1381â€&quot;4. 10.1056/NEJMp150291825853741 89.RatajczakWNiedzwiedzka-RystwejPTokarz-DeptuÅ‚aBDeptuÅ‚aW. Immunological memory cells." exact="Central" post="Eur J Immunol. (2018) 43:194â€&quot;203. 10.5114/ceji.2018.7739030135633 90.AminJafariAGhasemiS. The possible"/>
  <result pre="Available online at: https://www.bat.com/ (accessed April 24, 2020). 99.collab: EuractivBritish" exact="American" post="Tobacco Working on COVID-19 Vaccine Using Tobacco Leaves. (2020)."/>
  <result pre="Lancet. (2003) 361:2045â€&quot;6. 10.1016/S0140-6736(03)13615-X12814717 111.WuCYJanJTMaSHKuoCJJuanHFChengYSet al.. Small molecules targeting severe" exact="acute" post="respiratory syndrome human coronavirus. Proc Natl Acad Sci USA."/>
  <result pre="(2003) 361:2045â€&quot;6. 10.1016/S0140-6736(03)13615-X12814717 111.WuCYJanJTMaSHKuoCJJuanHFChengYSet al.. Small molecules targeting severe acute" exact="respiratory" post="syndrome human coronavirus. Proc Natl Acad Sci USA. (2004)"/>
  <result pre="361:2045â€&quot;6. 10.1016/S0140-6736(03)13615-X12814717 111.WuCYJanJTMaSHKuoCJJuanHFChengYSet al.. Small molecules targeting severe acute respiratory" exact="syndrome" post="human coronavirus. Proc Natl Acad Sci USA. (2004) 101:10012â€&quot;7."/>
  <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version). Mil Med Res. (2020) 7:4. 10.1186/s40779-020-0233-632029004 123.KimHYEoEYParkHKimYCParkSShinHJet"/>
  <result pre="10.1016/j.antiviral.2006.04.01416730806 125.YiLLiZYuanKQuXChenJWangGet al.. Small molecules blocking the entry of severe" exact="acute" post="respiratory syndrome coronavirus into host cells. J Virol. (2004)"/>
  <result pre="125.YiLLiZYuanKQuXChenJWangGet al.. Small molecules blocking the entry of severe acute" exact="respiratory" post="syndrome coronavirus into host cells. J Virol. (2004) 78:11334â€&quot;9."/>
  <result pre="al.. Small molecules blocking the entry of severe acute respiratory" exact="syndrome" post="coronavirus into host cells. J Virol. (2004) 78:11334â€&quot;9. 10.1128/JVI.78.20.11334-11339.200415452254"/>
  <result pre="al.. Herbal plants and plant preparations as remedial approach for" exact="viral" post="diseases. Virusdisease. (2015) 26:225â€&quot;36. 10.1007/s13337-015-0276-626645032 127.DenaroMSmeriglioABarrecaDDe FrancescoCOcchiutoCMilanoGet al.. Antiviral"/>
 </snippets>
</snippetsTree>
